Therapeutic measures in proteinuric nephropathy

Area of Science:

• Nephrology
• Pharmacology

Background:

• Proteinuria is a major risk factor for progressive kidney disease.
• Reducing proteinuria is crucial for slowing the decline of renal function in proteinuric nephropathies.

Purpose of the Study:

• To review therapeutic strategies for reducing proteinuria.
• To highlight the efficacy of renin-angiotensin-aldosterone system (RAAS) blockade and combination therapies.

Main Methods:

• Review of current literature on antiproteinuric treatments.
• Analysis of the mechanisms of action for ACE inhibitors and AT1-receptor antagonists (ARAs).
• Evaluation of adjunctive therapies including lifestyle modifications and other medications.

Main Results:

• RAAS blockade with ACE inhibitors or ARAs is a primary antiproteinuric strategy.
• Combined ACE inhibitor and ARA therapy shows superior antiproteinuric and renoprotective effects.
• Aldosterone antagonists, renin antagonists, statins, smoking cessation, weight loss, and dietary modifications also reduce proteinuria.

Conclusions:

• Combined RAAS blockade offers enhanced renoprotection.
• Comprehensive management including lifestyle changes and other medications is vital for controlling proteinuria.
• Targeting proteinuria is essential for preserving kidney function in various renal diseases.